Results 81 to 90 of about 240,836 (199)

Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis ...
Zara Saeed, Syeda Ariba Zehra, Sumyya Tariq, Rocio Pun Zumaran, Mounika Kotte, Zeeshan Hameed, Neeraj Joshi, Pushpa Kumari, Kanta Kumari, Awais Habib, Fawad Talat, Osama Taj, Jahanzeb Malik, Abida Perveen   +13 more
wiley   +1 more source

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Stroke: Vascular and Interventional Neurology
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa ...
Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk   +10 more
doaj   +1 more source

Neck‐vein thrombosis during spaceflight

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 24-34, January 2026.
Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley   +1 more source

Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report.

, 2023
PURPOSE: Apixaban is a direct-acting oral anticoagulant that selectively inhibits factor Xa. Reversal strategies utilized to treat factor Xa inhibitor-associated bleeding include andexanet alfa, prothrombin complex -concentrate (PCC), and activated PCC ...
Philp, Allan S, Stripp, Matthew P, DelBianco, John, MD, Jenniches, Daniel, Kerns, Abigail F   +4 more
core  

The incidence of thrombotic events with idarucizumab and andexanet alfa : a systematic review and meta-analysis

, 2020
© 2020 Elsevier Ltd. All rights reserved.Introduction: Direct thrombin inhibitor, dabigatran and factor Xa inhibitors, apixaban, edoxaban, and rivaroxaban (DOACs/NOACs), are currently the first-choice drugs in some indications.
Ferreira, Joaquim J, Rodrigues, André Oliveira, Costa, João, Caldeira, Daniel, Pinto, Fausto J., David, Cláudio   +5 more
core   +1 more source

The Selection of Andexanet Alfa vs. 4‐Factor Prothrombin Complex Concentrate for the Treatment of Life‐Threatening Hemorrhage

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Andexanet alfa and 4‐factor prothrombin complex concentrate (4F‐PCC) are used for the reversal of life‐threatening hemorrhages associated with oral Factor Xa inhibitors. Limited studies have examined factors influencing reversal agent selection and time to administration.
Kira Galeano, Rachel E. Culbreth, Jeffrey Brent, Alexandra Amaducci, Alyssa M. Falise, Anna G. Zmuda, Rita Farrah, David Liss, Charlotte Goldfine, Mari Costantini, Sharan Campleman, Paul Wax, Kim Aldy, Fortofoiu Mircea-Catalin   +13 more
wiley   +1 more source

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis

Pharmacotherapy
Previous meta‐analyses assessed andexanet alfa (AA) or prothrombin complex concentrate (PCC) products for the treatment of Factor Xa inhibitor (FXaI)‐associated major bleeding. However, they did not include recent studies or assess the impact of the risk
C. White, Kimberly Snow Caroti, Youssef Bessada, Adrián V. Hernández, W. Baker, P. Dobesh, H. van Haalen, K. Rhodes, Craig I. Coleman   +8 more
semanticscholar   +1 more source

Intracerebral Hemorrhage: Advances, Knowledge Gaps, and Future Directions

MedComm, Volume 6, Issue 11, November 2025.
This review provides a comprehensive synthesis of current research on the epidemiology, pathophysiological mechanisms, imaging characteristics, treatment delays, clinical management strategies, neural repair, and prognostic prediction of intracerebral hemorrhage (ICH).
Tao Liu, Weiwei Jiang, Minzhi Zhang, Shangzhi Xiong, Linan Chen, Xiaoying Chen, Rongcai Jiang   +6 more
wiley   +1 more source

Stroke prevention in atrial fibrillation: A narrative review of current evidence and emerging strategies

European Journal of Clinical Investigation, Volume 55, Issue 9, September 2025.
Effective stroke prevention in AF requires a comprehensive holistic approach incorporating appropriate risk stratification, guideline‐adherent anticoagulation and management of underlying cardiovascular conditions and other comorbidities. The ABC pathway, supported by characterisation using the 4S‐AF framework, provides a structured approach to ...
Amir Askarinejad, Deirdre A. Lane, Parham Sadeghipour, Majid Haghjoo, Gregory Y. H. Lip   +4 more
wiley   +1 more source

Evaluation of clinical outcomes of 4-factor prothrombin complex concentrate versus andexanet alfa in the treatment of intracerebral hemorrhage [PDF]

, 2020
Purpose: Oral anticoagulants account for up to 20% of intracerebral hemorrhages (ICH) with one-year mortality estimated as high as 54%. Several studies have examined the use of 4-Factor prothrombin complex concentrate (4F-PCC) and andexanet alfa in the ...
Gopalani, Radhan, De Los Rios La Rosa, Felipe, Clarke, Heidi, Kline, Jonatha, Guizan Corrales, Eduardo, Wolfel, Thomas   +5 more
core